These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 7667557)

  • 1. Some practical improvements in the continual reassessment method for phase I studies.
    Goodman SN; Zahurak ML; Piantadosi S
    Stat Med; 1995 Jun; 14(11):1149-61. PubMed ID: 7667557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The continual reassessment method in cancer phase I clinical trials: a simulation study.
    Chevret S
    Stat Med; 1993 Jun; 12(12):1093-108. PubMed ID: 8210815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive design improvements in the continual reassessment method for phase I studies.
    Heyd JM; Carlin BP
    Stat Med; 1999 Jun; 18(11):1307-21. PubMed ID: 10399198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of phase I cancer clinical trial designs.
    Ahn C
    Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A curve-free method for phase I clinical trials.
    Gasparini M; Eisele J
    Biometrics; 2000 Jun; 56(2):609-15. PubMed ID: 10877324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of two phase I trial designs.
    Korn EL; Midthune D; Chen TT; Rubinstein LV; Christian MC; Simon RM
    Stat Med; 1994 Sep; 13(18):1799-806. PubMed ID: 7997713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A web tool for designing and conducting phase I trials using the continual reassessment method.
    Wages NA; Petroni GR
    BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.